Drugs / Endocine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02998996 | Sep 2016 → Jun 2017 | influenza | Eurocine Vaccines AB | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01473810 Background | Nov 2011 → Mar 2012 | HIV infectious disease | Oslo University Hospital | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-05-10 | Bionor Immuno AS | Successfully results from clinical study with Vacc-4x and Endocine bionorholding.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Endocine | “in conjunction with Endocine, a newly developed and documented mucosal adjuvant” NCT01473810 ↗ |
| Route | Intranasal | “300 µl Endocine divided into two administrations, one for each nose cavity” NCT01473810 ↗ |